Literature DB >> 21356216

Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety.

Satoshi Yamaori1, Juri Ebisawa, Yoshimi Okushima, Ikuo Yamamoto, Kazuhito Watanabe.   

Abstract

AIMS: In this study, we examined the inhibitory effects of Δ(9)-tetrahydrocannabinol (Δ(9)-THC), cannabidiol (CBD), and cannabinol (CBN), the three major cannabinoids, on the activity of human cytochrome P450 (CYP) 3A enzymes. Furthermore, we investigated the kinetics and structural requirement for the inhibitory effect of CBD on the CYP3A activity. MAIN
METHODS: Diltiazem N-demethylase activity of recombinant CYP3A4, CYP3A5, CYP3A7, and human liver microsomes (HLMs) in the presence of cannabinoids was determined. KEY
FINDINGS: Among the three major cannabinoids, CBD most potently inhibited CYP3A4 and CYP3A5 (IC(50)=11.7 and 1.65 μM, respectively). The IC(50) values of Δ(9)-THC and CBN for CYP3A4 and CYP3A5 were higher than 35 μM. For CYP3A7, Δ(9)-THC, CBD, and CBN inhibited the activity to a similar extent (IC(50)=23-31 μM). CBD competitively inhibited the activity of CYP3A4, CYP3A5, and HLMs (K(i)=1.00, 0.195, and 6.14 μM, respectively). On the other hand, CBD inhibited the CYP3A7 activity in a mixed manner (K(i)=12.3 μM). Olivetol partially inhibited all the CYP3A isoforms tested, whereas d-limonene showed lack of inhibition. The lesser inhibitory effects of monomethyl and dimethyl ethers of CBD indicated that the ability of CYP3A inhibition by the cannabinoid attenuated with the number of methylation on the phenolic hydroxyl groups in the resorcinol moiety. SIGNIFICANCE: This study indicated that CBD most potently inhibited catalytic activity of human CYP3A enzymes, especially CYP3A4 and CYP3A5. These results suggest that two phenolic hydroxyl groups in the resorcinol moiety of CBD may play an important role in the CYP3A inhibition.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21356216     DOI: 10.1016/j.lfs.2011.02.017

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  55 in total

Review 1.  Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

Authors:  Javier Fernández-Ruiz; Onintza Sagredo; M Ruth Pazos; Concepción García; Roger Pertwee; Raphael Mechoulam; José Martínez-Orgado
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

Review 2.  The Impact of Perioperative Cannabis Use: A Narrative Scoping Review.

Authors:  Karim S Ladha; Varuna Manoo; Ali-Faizan Virji; John G Hanlon; Alexander Mclaren-Blades; Akash Goel; Duminda N Wijeysundera; Lakshmi P Kotra; Carlos Ibarra; Marina Englesakis; Hance Clarke
Journal:  Cannabis Cannabinoid Res       Date:  2019-12-06

3.  Human Pharmacokinetic Parameters of Orally Administered Δ9-Tetrahydrocannabinol Capsules Are Altered by Fed Versus Fasted Conditions and Sex Differences.

Authors:  Stephanie Lunn; Patrick Diaz; Shannon O'Hearn; Shaina P Cahill; Alexia Blake; Kelly Narine; Jason R B Dyck
Journal:  Cannabis Cannabinoid Res       Date:  2019-12-06

Review 4.  Marijuana Legalization: Impact on Physicians and Public Health.

Authors:  Samuel T Wilkinson; Stephanie Yarnell; Rajiv Radhakrishnan; Samuel A Ball; Deepak Cyril D'Souza
Journal:  Annu Rev Med       Date:  2015-10-19       Impact factor: 13.739

5.  Marijuana use by middle-aged and older adults in the United States, 2015-2016.

Authors:  Benjamin H Han; Joseph J Palamar
Journal:  Drug Alcohol Depend       Date:  2018-09-06       Impact factor: 4.492

Review 6.  Marijuana Use in Epilepsy: The Myth and the Reality.

Authors:  Kamil Detyniecki; Lawrence Hirsch
Journal:  Curr Neurol Neurosci Rep       Date:  2015-10       Impact factor: 5.081

Review 7.  Neonatal cytochrome P450 CYP3A7: A comprehensive review of its role in development, disease, and xenobiotic metabolism.

Authors:  Haixing Li; Jed N Lampe
Journal:  Arch Biochem Biophys       Date:  2019-08-22       Impact factor: 4.013

Review 8.  Cannabinoids: Current and Future Options to Treat Chronic and Chemotherapy-Induced Neuropathic Pain.

Authors:  Henry L Blanton; Jennifer Brelsfoard; Nathan DeTurk; Kevin Pruitt; Madhusudhanan Narasimhan; Daniel J Morgan; Josée Guindon
Journal:  Drugs       Date:  2019-06       Impact factor: 9.546

9.  Persistent Hypersomnolence Following Clobazam in a Child With Epilepsy and Undiagnosed CYP2C19 Polymorphism.

Authors:  Katherine E Hamilton; Chasity M Shelton; James Wheless; Stephanie J Phelps
Journal:  J Pediatr Pharmacol Ther       Date:  2020

Review 10.  Cannabinoids and Epilepsy.

Authors:  Evan C Rosenberg; Richard W Tsien; Benjamin J Whalley; Orrin Devinsky
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.